

Supplementary Information

Design and development of salen-type Schiff bases as potential antivirus agents: Experimental and theoretical approach

Sunil Kumar & Mukesh Choudhary*

Department of Chemistry, National Institute of Technology Patna, Patna 800 005, Bihar, India

*E-mail: mukesh@nitp.ac.in

Sl. No.	Contents	Pg. No.
1	Fig. S1 — ¹ H-NMR spectrum of salen-type compound LH ₂	4
2	Fig. S2 — ¹³ C-NMR spectrum of the salen-type compound LH ₂	4
3	Fig. S3 — ¹ H-NMR spectrum of the salen-type compound L ¹ H ₂	5
4	Fig. S4 — ¹³ C-NMR spectrum of the salen-type compound L ¹ H ₂	5
5	Fig. S5 — ¹ H-NMR spectrum of the salen-type compound L ² H ₂	6
6	Fig. S6 — ¹³ C-NMR spectrum of the salen-type compound L ² H ₂	6
7	Fig. S7 — FT-IR spectrum of salen-type compound LH ₂	7
8	Fig. S8 — FT-IR spectrum of salen-type compound L ¹ H ₂	7
9	Fig. S9 — FT-IR spectrum of salen-type compound L ² H ₂	8
10	Fig. S10 — Deformation density, crystal void and promolecular density of the salen-type compound LH ₂	8
11	Fig. S11 — CE-B3LYP estimates of energy components and total energies (kJ/mol) for the closest intermolecular interactions in the salen-type compound LH ₂	9
12	Fig. S12 — Optimized and molecular structures of salen-type compounds LH ₂ -L ⁴ H ₂	9
13	Fig. S13 — HOMO-LUMO energies and energy gap of salen-type compounds LH ₂ , L ¹ H ₂ and L ² H ₂	10
14	Fig. S14 — HOMO-LUMO energies and energy gap of salen-type compounds L ¹ H ₂ and L ² H ₂	10
15	Fig. S15 — MEPs presentation including (a) radical frontier density, (b) electrophilic and nucleophilic frontier density (c) surface density for salen-type compounds LH ₂ , L ¹ H ₂ and L ² H ₂	11
16	Fig. S16 — MEPs presentation including (a) radical frontier density, (b) electrophilic and nucleophilic frontier density (c) surface density for salen-type compounds L ³ H ₂ and L ⁴ H ₂	11
17	Fig. S17 — Graphical view of overall model quality and residue scores of SARS-CoV-2 main protease (PDB ID: 7O46)	12
18	Fig. S18 — The representation of docked LH ₂ compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively	12

19	<p>Fig. S19 — The representation of docked L^1H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively</p>	13
20	<p>Fig. S20 — The representation of docked L^2H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively</p>	14
21	<p>Fig. S21 — The representation of docked L^3H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours</p>	15
22	<p>Fig. S22 — The representation of docked L^4H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively</p>	16
23	<p>Fig. S23 — Two-dimensional diagrams of salen type compounds L^1H_2-L^4H_2 with SARS-CoV-2 main protease (M^{pro})</p>	17
24	<p>Fig. S24 — Two-dimensional Lig-plot image of salen type compounds L^1H_2-L^4H_2 with SARS-CoV-2 main protease (M^{pro})</p>	17
25	<p>Fig. S25 — The representation of docked LH_2 compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively</p>	18
26	<p>Fig. S26 — The representation of docked L^1H_2 compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours;</p>	19

	(b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively	
27	Fig. S27 — The representation of docked L ² H ₂ compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively	20
28	Fig. S28 — The representation of docked L ³ H ₂ compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively	21
29	Fig. S29 — The representation of docked L ⁴ H ₂ compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively	22
30	Fig. S30 — Two-dimensional interactions of docked ligands LH ₂ -L ⁴ H ₂ inside the DNA polymerase IV (PDB ID: 5YUX) generated by Lig Plot	23
31	Fig. S31 — Swiss target prediction of synthesized salen type compounds (L ¹ H ₂ -L ² H ₄)	23
32	Fig. S32 — The bioavailability radar prediction of synthesized salen type compounds(L ¹ H ₂ -L ² H ₄)	24
33	Table S1 — Bond distances (Å) and bond angles (°) for salen-type compound LH ₂	24
34	Table S2 — Hydrogen bonds for salen type compoundLH ₂ [Å and °]	26
35	Table S3 — The Swiss-ADME computed parameters results of synthesized salen type compoundsLH ₂ -L ⁴ H ₂	26
36	Table S4 — The physiochemical properties of synthesized salen type compounds (LH ₂ -L ⁴ H ₂)	27
37	Table S5 — Pharmacokinetics properties of the investigated salen-type compounds (LH ₂ -L ⁴ H ₂)	27




Fig. S1 — $^1\text{H-NMR}$ spectrum of salen-type compound LH_2




Fig. S2 — $^{13}\text{C-NMR}$ spectrum of the salen-type compound LH_2




Fig. S3 — ^1H -NMR spectrum of the salen-type compound L^1H_2




Fig. S4 — ^{13}C -NMR spectrum of the salen-type compound L^1H_2




Fig. S5 — 1H -NMR spectrum of the salen-type compound L^2H_2




Fig. S6 — ^{13}C -NMR spectrum of the salen-type compound L^2H_2




Fig. S7 — FT-IR spectrum of salen-type compound LH_2




Fig. S8 — FT-IR spectrum of salen-type compound L^1H_2




Fig. S9 — FT-IR spectrum of salen-type compound L^2H_2




Fig. S10 — Deformation density, crystal void and promolecular density of the salen-type compound LH_2

	N	Symp	R	Electron Density	E_ele	E_pol	E_dis	E_rep	E_tot
	2	x, y, z	18.74	HF/3-21G	4.8	-0.2	-7.8	0.0	-2.3
	2	x, y, z	18.09	HF/3-21G	-3.2	-0.1	-5.1	0.0	-7.9
	4	-x, y+1/2, -z+1/2	4.70	HF/3-21G	-9.2	-6.5	-70.2	34.7	-48.7
	2	x, y, z	6.11	HF/3-21G	-24.8	-6.0	-36.0	13.6	-50.6

Energy Model	k_ele	k_pol	k_disp	k_rep
CE-HF ... HF/3-21G electron densities	1.019	0.651	0.901	0.811
CE-B3LYP ... B3LYP/6-31G(d,p) electron densities	1.057	0.740	0.871	0.618

Fig. S11 — CE-B3LYP estimates of energy components and total energies (kJ/mol) for the closest intermolecular interactions in the salen-type compound LH₂




Fig. S12 — Optimized and molecular structures of salen-type compounds LH₂- L⁴H₂




Fig. S13 — HOMO-LUMO energies and energy gap of salen-type compounds LH_2 , L^1H_2 and L^2H_2




Fig. S14 — HOMO-LUMO energies and energy gap of salen-type compounds L^1H_2 and L^2H_2




Fig. S15 — MEPs presentation including (a) radical frontier density, (b) electrophilic and nucleophilic frontier density (c) surface density forsalen-type compounds LH_2 , L^1H_2 and L^2H_2




Fig. S16 — MEPs presentation including (a) radical frontier density, (b) electrophilic and nucleophilic frontier density (c) surface density for salen-type compounds L^3H_2 and L^4H_2




Fig. S17 — Graphical view of overall model quality and residue scores of SARS-CoV-2 main protease (PDB ID: 7O46)




Fig. S18 — The representation of docked LH₂ compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S19 — The representation of docked L^1H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S20 — The representation of docked L²H₂ compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S21 — The representation of docked L^3H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours




Fig. S22 — The representation of docked L^4H_2 compound with SARS-CoV-2 main protease for COVID-19 (PDB ID: 7O46) with its focused view for interacting residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S23 — Two-dimensional diagrams of salen type compounds L^1H_2 - L^4H_2 with SARS-CoV-2 main protease (M^{Pro})




Fig. S24 — Two-dimensional Lig-plot image of salen type compounds L^1H_2 - L^4H_2 with SARS-CoV-2 main protease (M^{Pro})




Fig. S25 — The representation of docked LH₂ compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S26 — The representation of docked L¹H₂ compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S27 — The representation of docked L2H2compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S28 — The representation of docked L^3H_2 compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S29 — The representation of docked L^4H_2 compound inside the HIV-1 virus (PDB ID: 1UUI) with its focused view for interacting nucleotide residues along with H-bond and intermolecular interactions; (a) Aromatic receptor surface represented by blue (Edge) and light orange (face) colours; (b) H-bond donor and acceptor meshes represented by pink and light green colours, respectively; (c) Hydrophobic pocket represented with blue and brown colours; (d) Ionizability receptor surface represented by blue (basic) and red (acidic) colours (e) Interpolated charge receptor surface represented by blue and red colours; (f) SAS receptor surface represented by blue and light green colours, respectively




Fig. S32 — The bioavailability radar prediction of synthesized salen type compounds(L¹H₂-L²H₄)

Table S1 — Bond distances (Å) and bond angles (°) for salen-type compound LH ₂		
Ligand	Bond lengths (Å)	Bond angles (°)
LH ₂	C(1)-C(2) 1.382(8)	C(2)-C(1)-C(6) 119.6(5)
	C(1)-C(6) 1.394(8)	C(2)-C(1)-Br(1) 119.0(4)
	C(1)-Br(1) 1.886(6)	C(6)-C(1)-Br(1) 121.3(4)
	C(2)-C(3) 1.389(7)	C(1)-C(2)-C(3) 120.2(5)
	C(2)-H(2) 0.9400	C(1)-C(2)-H(2) 119.9
	C(3)-C(4) 1.410(7)	C(3)-C(2)-H(2) 119.9
	C(3)-C(7) 1.471(7)	C(2)-C(3)-C(4) 119.8(5)
	C(4)-O(1) 1.341(7)	C(2)-C(3)-C(7) 119.8(5)
	C(4)-C(5) 1.396(7)	C(4)-C(3)-C(7) 120.4(5)
	C(5)-C(6) 1.355(9)	O(1)-C(4)-C(5) 119.6(5)
	C(5)-H(5) 0.9400	O(1)-C(4)-C(3) 121.7(5)
	C(6)-H(6) 0.9400	C(5)-C(4)-C(3)
	C(7)-N(1)	

1.266(8)		118.7(5)
C(7)-H(7)	0.9400	C(6)-C(5)-C(4) 120.9(5)
C(8)-N(1)	1.466(7)	C(6)-C(5)-H(5) 119.5
C(8)-C(8)#1	1.488(11)	C(4)-C(5)-H(5) 119.5
C(8)-H(8A)	0.9800	C(5)-C(6)-C(1) 120.8(5)
C(8)-H(8B)	0.9800	C(5)-C(6)-H(6) 119.6
O(1)-H(1)	0.8300	C(1)-C(6)-H(6) 119.6
		N(1)-C(7)-C(3) 122.7(5)
		N(1)-C(7)-H(7) 118.7
		C(3)-C(7)-H(7) 118.7
		N(1)-C(8)-C(8)#1 110.1(6)
		N(1)-C(8)-H(8A) 109.6
		C(8)#1-C(8)-H(8A) 109.6
		N(1)-C(8)-H(8B) 109.6
		C(8)#1-C(8)-H(8B) 109.6
		H(8A)-C(8)-H(8B) 108.1
		C(7)-N(1)-C(8) 118.3(5)
		C(4)-O(1)-H(1) 109.5
Symmetry transformations used to generate equivalent atoms: #1 -x+1,-y+1,-z+2		

D-H...A	d(D-H)	d(H...A)	d(D...A)	<(DHA)
C(8)-H(8B)...N(1)#2	0.98	2.63	3.583(9)	165.1
O(1)-H(1)...N(1)	0.83	1.87	2.609(6)	147.8
C(8)-H(8B)...N(1)#2	0.98	2.63	3.583(9)	165.1
Symmetry transformations used to generate equivalent atoms: #1 – x+1,-y+1,-z+2 #2 x,-y+1/2, z+1/2				

Swiss-ADME computed parameter	CQ ^a	HCQ ^a	LH ₂	L ¹ H ₂	L ² H ₂	L ³ H ₂	L ⁴ H ₂
M.W (150-500g/mol)	285.43	287.40	426.10	406.09	486.15	771.90	448.30
H-acceptors (≤10)	2	3	4	4	6	4	12
H-donors (≤5)	1	2	2	2	2	2	2
Log P (0.7-5.0)	4.15	3.32	4.16	5.24	4.17	5.05	2.26
No. of violation (Rule of 5)	0	0	0	1	0	2	1
TPSA (20-130 Å ²)	28.16	48.39	65.18	65.18	83.64	65.18	248.46
Rotatable bonds (<9)	7	7	5	5	7	5	9
Log S (>-6)	-3.95	-3.37	-4.49	-5.66	-4.82	-5.76	-7.34
Fraction Csp ³ (>0.25)	0.5	0.47	0.12	0.12	0.22	0.12	0.12

Table S4 — The physiochemical properties of synthesized salen type compounds (LH ₂ -L ⁴ H ₂)					
Physiochemical Property	LH ₂	L ¹ H ₂	L ² H ₂	L ³ H ₂	L ⁴ H ₂
Molecular Weight	426.10	46.09	486.15	771.90	448.30
Log P	4.541	5.346	4.359	6.534	2.932
Log S	-4.596	-5.314	-5.284	-4.835	-4.591
Log D	3.458	2.803	3.264	2.487	1.481
nHA	4	4	6	4	16
nHD	2	2	2	2	2
TPSA	65.18	65.18	83.64	65.18	237.74
nRot	5	5	7	5	9
nRing	2	2	2	2	2
MaxRing	6	6	6	6	6
nHet	6	8	8	8	16
fChar	0	0	0	0	0
nRig	14	14	14	14	18

Table S5 — Pharmacokinetics properties of the investigated salen-type compounds (LH ₂ -L ⁴ H ₂)					
Absorption					
Property	LH ₂	L ¹ H ₂	L ² H ₂	L ³ H ₂	L ⁴ H ₂
Pgp-substrate	0.003	0.927	0.004	0.279	0.867
HIA	0.025	0.002	0.101	0.005	0.02
F _{20%}	0.265	0.265	0.165	0.201	0.004
F _{30%}	0.031	0.997	0.01	0.669	0.001
Caco-2 Permeability	-5.164	-5.328	-5.36	-5.247	-4.927
Distribution					
PPB	96.45 %	100.6 %	97.56 %	98.52 %	98.39 %
VD	0.983	0.696	0.877	0.629	1.367
BBB Penetration	0.24	0.101	0.131	0.029	0.981
Fu	6.576 %	0.941 %	3.775 %	2.608 %	4.193 %
Metabolism					
CYP1A2 inhibitor	0.749	0.468	0.816	0.591	0.499
CYP1A2 substrate	0.618	0.847	0.923	0.54	0.093

CYP2C19 inhibitor	0.168	0.077	0.073	0.025	0.302
CYP2C9 inhibitor	0.108	0.167	0.058	0.084	0.531
CYP2D6 inhibitor	0.967	0.757	0.87	0.137	0.084
Excretion					
CL	0.83	1.795	1.045	0.674	0.809
T _{1/2}	0.255	0.084	0.59	0.023	0.309
Toxicity					
hERG Blockers	0.016	0.034	0.183	0.118	0.232
H-HT	0.049	0.048	0.084	0.084	0.148
DILI	0.573	0.912	0.616	0.555	0.962
Eye corrosion	0.955	0.004	0.24	0.01	0.003
Respiratory Toxicity	0.843	0.794	0.922	0.909	0.746
Environmental toxicity					
IGC ₅₀	5.282	5.406	5.165	6.072	4.623
LC ₅₀ FM	6.214	6.455	6.481	6.833	6.081
LC ₅₀ DM	6.465	6.369	6.776	6.716	5.899
Tox21 pathway					
NR-AR-LBD	0.006	0.031	0.021	0.093	0.566
SR-MMP	0.932	0.97	0.911	0.975	0.994